Quantcast

Industry news that matters to you.  Learn more

Circadian Granted Key Strategic VEGF-D Patent in USA for Diagnostic Applications

Circadian Technologies has reported that its subsidiary company, Vegenics Limited, has been granted US Patent 7785803 claiming diagnostic kits for the detection of VEGF-D in human samples such as blood.

VEGF-D, a major novel target for cancer and other diseases, has been shown to be a prognostic indicator of survival or disease progression in a number of different cancer types as well as a biomarker for various respiratory diseases.